POST Online Media Lite Edition


EC approves merger between Amcor and Bemis, subject to conditions

Staff Writer |
The European Commission has approved the merger between Amcor and Bemis.

Article continues below

Both companies manufacture flexible packaging products worldwide. The approval is conditional on the divestment of Bemis' medical packaging business in Europe.

Amcor and Bemis are both global manufacturers of packaging solutions worldwide, supplying a broad range of rigid and flexible packaging products for many different sectors, including the food, consumer, medical and pharmaceutical industries.

The Commission examined in particular the effects of the proposed transaction on competition in the markets for the supply of flexible packaging for medical use and for food products in the European Economic Area (EEA), where the activities of Amcor and Bemis overlap.

As regards flexible packaging for medical use, Amcor and Bemis are the most significant players in the EEA and have been competing closely.

The merged entity would have created a player three times larger than the second largest supplier, on a fragmented market with many small suppliers.

The Commission found that barriers of entry are extremely high on this market, and customers do not easily switch suppliers. As a result, the Commission was concerned that the transaction as notified would negatively affect competition on the market for flexible packaging for medical use and could lead to higher prices, less choice and less innovation.

As regards flexible packaging for food products, the Commission concluded that the proposed merger would raise no competition concerns due to the presence of a large number of alternative suppliers, lower barriers to entry and because it is easier for customers to switch to alternative suppliers.

To address the Commission's competition concerns, Amcor and Bemis offered to divest Bemis' entire medical packaging business in the EEA.

The commitments fully address the Commission's concerns as they remove the entire overlap between the companies' activities in the supply of flexible packaging for medical use in the EEA.

Therefore, the Commission concluded that the proposed transaction, as modified by the commitments, would no longer raise competition concerns in the EEA. The decision is conditional upon full compliance with the commitments.

Given the worldwide scope of the companies' activities, the Commission has cooperated closely with the US Department of Justice.

What to read next

Amcor to acquire U.S. plastics business for $280 million
Bemis to close factories to reduce cost structure
Platinum Equity completes acquisition of MACtac